| dc.contributor.author | Hernández-Sánchez, María | |
| dc.contributor.author | Kotaskova, Jana | |
| dc.contributor.author | Rodríguez Vicente, Ana E. | |
| dc.contributor.author | Radova, Lenka | |
| dc.contributor.author | Tamborero, David | |
| dc.contributor.author | Abáigar Alvarado, María | |
| dc.contributor.author | Plevova, Karla | |
| dc.contributor.author | Benito Sánchez, Rocío | |
| dc.contributor.author | Tom, Nikola | |
| dc.contributor.author | Quijada Álamo, Miguel | |
| dc.contributor.author | Bikos, Vasileos | |
| dc.contributor.author | Martín, Ana África | |
| dc.contributor.author | Pal, Karol | |
| dc.contributor.author | García de Coca, Alfonso | |
| dc.contributor.author | Doubek, Michael | |
| dc.contributor.author | López-Bigas, Nuria | |
| dc.contributor.author | Hernández Rivas, Jesús María | |
| dc.contributor.author | Pospisilova, Sarka | |
| dc.date.accessioned | 2025-01-23T12:12:59Z | |
| dc.date.available | 2025-01-23T12:12:59Z | |
| dc.date.issued | 2019 | |
| dc.identifier.citation | Hernández-Sánchez, M., Kotaskova, J., Rodríguez, A. E., Radova, L., Tamborero, D., Abáigar, M., ... & Pospisilova, S. (2019). CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase. Leukemia, 33(2), 518-558. | es_ES |
| dc.identifier.issn | 0887-6924 | |
| dc.identifier.uri | http://hdl.handle.net/10366/162376 | |
| dc.description.abstract | [SP]El artículo describe los mecanismos de evolución clonal en pacientes con leucemia linfocítica crónica comparando aquellos con progresión clínica con aquellos con enfermedad estable durante años, sin tratamiento. El análisis del exoma se realizó mediante secuenciación masiva en diferentes estadios de la enfermedad. Este trabajo ha mejorado nuestro conocimiento de la compleja biología subyacente a la heterogeneidad de la LLC así como de los eventos moleculares implicados en su evolución y muestra la importancia de monitorizar clones tumorales mediante NGS en pacientes con LLC | es_ES |
| dc.description.sponsorship | The research leading to these results has mainly received funding from the European Union Seventh Framework Programme [FP7/2007–2013] under Grant Agreement no 306242-NGS-PTL. In addition, this work was supported by grants from the Spanish Fondo de Investigaciones Sanitarias PI15/01471, PI18/01500, Instituto de Salud Carlos III (ISCIII), European Regional Development Fund (ERDF) “Una manera de hacer Europa”, “Consejería de Educación, Junta de Castilla y León” (SA085U16), “Proyectos de Investigación del SACYL”, Spain: GRS 994/A/14, BIO/SA10/14, BIO/SA31/13, GRS 1172/A/15,“Fundación Memoria Don Samuel Solórzano Barruso”, by grants (RD12/0036/0069) from Red Temática de Investigación Cooperativa en Cáncer (RTICC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) CB16/12/00233 and USAL "Programa XIII". M. Hernández-Sánchez is supported by FEHH-Janssen (“Sociedad Española de Hematología y Hemoterapia”). M Quijada-Álamo is supported by an “Ayuda Predoctoral de la Junta de Castilla y León” (JCYL-EDU/529/2017). We are grateful to I. Rodríguez, S. González, T.Prieto, M. Á. Ramos, A. Martín, A. Díaz, A. Simón, M.del Pozo, V. Gutiérrez and S. Pujante from Centro de Investigación del Cáncer, Salamanca, for their technical assistance. D. Tamborero is supported by project SAF2015–74072-JUN, which is funded by the Agencia Estatal de Investigación (AEI) and Fondo Europeo de Dearrollo Regional (FEDER). This work was supported by Seventh Framework Programme (NGS-PTL/2012–2015/no.306242) and Ministry of Education, Youth and Sports (2013–2015, no. 7E13008); by the Ministry of Education, Youth and Sports of the Czech Republic under the CEITEC 2020 project (LQ1601); by the Ministry of Health, Czech Republic - conceptual development of research organization (FNBr, 65269705); by the Specific University Research (nr. MUNI/A/0968/2017) provided by MEYS; and by the project CZ.02.1.01/0.0/0.0/16_013/0001634 National Center for Medical Genomic - modernization of infrastructure and research of genetic variation in the population, funded by OP RDE. We acknowledge the CF Genomics CEITEC MU supported by the NCMG research infrastructure (LM2015091 funded by MEYS CR) for their support with obtaining the scientific data presented in this paper. We acknowledge S. Takacova from CEITEC MU for her help with the sample selection and processing. | es_ES |
| dc.language.iso | eng | es_ES |
| dc.subject | Chronic lymphocytic leukaemia | es_ES |
| dc.subject | Genetics research | es_ES |
| dc.title | CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase | es_ES |
| dc.type | info:eu-repo/semantics/article | es_ES |
| dc.relation.publishversion | https://doi.org/10.1038/S41375-018-0255-1 | es_ES |
| dc.identifier.doi | 10.1038/s41375-018-0255-1 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
| dc.identifier.essn | 1476-5551 | |
| dc.journal.title | Leukemia | es_ES |
| dc.volume.number | 33 | es_ES |
| dc.issue.number | 2 | es_ES |
| dc.page.initial | 518 | es_ES |
| dc.page.final | 558 | es_ES |
| dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |
